|
|
|
Unique Th1/Th2 Phenotypes Induced During Priming and Memory Phases Using IL-12 or IL-28B Vaccine Adjuvants in rhesus macaques. |
|
| Adjuvant compounds are usually included in vaccination in order to bolster total vaccine-specific responses or to tailor an immune response towards a desired endpoint, such as the production of Interferon gamma or an increase in antibody titers. |
|
|
Efficacy of Shanvac-B recombinant DNA hepatitis B vaccine in health care workers of Northern India. |
|
| Health care workers (HCWs) constitute a high-risk population of HBV infection. There are limited data on the efficacy of vaccination in HCWs in India. This study was to evaluate the efficacy of indigenous recombinant hepatitis B vaccine, Shanvac-B, in HCWs. |
|
|
Vaccination of Chickens with DNA Vaccine Encoding Eimeria acervulina 3-1E and Chicken IL-15 Offers Protection. |
|
Vaccination of Chickens with DNA Vaccine Encoding Eimeria acervulina 3-1E and Chicken IL-15 Offers Protection Against Homologous Challenge.
Eimeria acervulina 3-1E antigen gene and mature chicken interleukin 15 (mChIL-15) gene were cloned into expression vector pcDNA3.1(+) in different forms, produced DNA vaccine pcDNA3.1-3-1E, and pcDNA3.1-3-1E-linker-mChIL-15 co-expressing E. acervulina 3-1E gene and mChIL-15 gene, respectively. |
|
|
Genetic immunization: Bacteria as Dna vaccine delivery vehicles. |
|
| The so-called DNA vaccination represents one of the most notable tools under development in the field of vaccinology. The concept of administering the gene coding for any given protective antigen and make responsible vaccinee's own cells to produce the protein appeals as too simple to be true. |
|
|
Cytokine-FC Fusion Genes as Molecular Adjuvants for DNA Vaccines. |
|
| The use of gene constructs for DNA immunization offers several potential advantages over other commonly used vaccine approaches: (1) full-length cDNA provides multiple potential class I and class II epitopes, thus bypassing limitations of MHC restriction; (2) bacterial plasmid DNA contains immunogenic unmethylated CpG motifs (immunostimulatory sequences) that may act as a potent immunological adjuvant; and (3) DNA is relatively simple to purify in large quantities. |
|
|
Integral Molecular Announces Key Patent Issued on Lipoparticle Technology for Deriving High Concentrations of Cell-free Membrane Proteins. |
|
| PHILADELPHIA--(BUSINESS WIRE)--Integral Molecular, Inc. today announced the issuance of a key patent covering its technology for deriving high concentrations of membrane proteins. The patent, issued by the U.S. Patent and Trademark Office, covers the core composition of Integral Molecular’s Lipoparticle technology, a novel cell-free format for deriving highly-concentrated membrane proteins for antibody development, drug discovery, and biomedical research. Integral membrane proteins, such as G protein-coupled receptors (GPCRs) and ion channels, comprise about a third of existing drug targets, and Lipoparticles provide a means of isolating and characterizing antibodies and drugs against these proteins. Lipoparticle technology stems from research conducted at the University of Pennsylvania and published in the journals Science, PNAS, and Journal of Virology. |
|
|
Preparation of Poly(Lactic Acid) (PLA) and Poly(Ethylene Oxide) (PEO) Nanoparticles as Carriers for Gene Delivery. |
|
INTRODUCTION New nanoparticulate blend compositions based on poly(D,L lactic-co-glycolic acid) (PLGA) and poly(ethylene oxide) (PEO) derivatives have been designed as transmucosal gene carriers. These nanosystems benefit from the inherent biodegradability and low toxicity of their components and the mild conditions required for their preparation. In addition, specific advantages of these nanoparticles for in vivo gene delivery are (1) their adequate DNA loading capacity, (2) their ability to control the release of the encapsulated DNA for extended periods of time while preserving its delicate conformational structure as well as its biological activity, and (3) their capacity to overcome the nasal mucosa barrier and transport the associated model DNA vaccine, leading to a significant systemic immune response against the encoded protein. This protocol describes the preparation and characterization of DNA-loaded nanoparticles composed of poly(lactic acid) (PLA) and PEO and the use of these particles as transmucosal gene delivery carriers.
Source … |
|
|
Vical Reports Second Quarter 2010 Financial Results and Progress in Key Programs. |
|
SAN DIEGO, Aug. 3, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated ( VICL - news - people ) (Nasdaq:VICL) today reported financial results for the three months and six months ended June 30, 2010. Revenues decreased to $2.1 million for the second quarter of 2010 from $4.0 million for the second quarter of 2009, primarily as a result of a $1.5 million milestone payment in 2009 from Merck & Co. ( MRK - news - people ), Inc., based on Merck's ongoing Phase 1 clinical-stage development of an investigational cancer vaccine. Operating expenses increased to $10.6 million for the second quarter of 2010 from $9.8 million for the second quarter of 2009. The net loss was $8.4 million, or $0.15 per share, for the second quarter of 2010, compared with $6.0 million, or $0.14 per share, for the second quarter of 2009.
|
|
|
Electroporation enhances immune responses and protection induced by a bovine viral diarrhea virus DNA vaccine in newborn calves with maternal antibodies. |
|
Bovine viral diarrhea virus (BVDV) is one of the major pathogens in cattle. In this study, newborn calves with maternal antibodies were vaccinated with a BVDV DNA vaccine, either by conventional intramuscular (IM) injection or with the TriGrid Delivery System for IM delivery (TDS-IM). The calves vaccinated with the TDS-IM developed more rapidly and effectively BVDV-specific humoral and cell-mediated immune responses in the presence of maternal antibodies. Overall, the immune responses induced by delivery with the TDS-IM remained stronger than those elicited by conventional IM injection of the BVDV DNA vaccine. Accordingly, electroporation-mediated delivery of the BVDV DNA vaccine resulted in close to complete protection from clinical signs of disease, while conventional IM administration did not fully prevent morbidity and mortality following challenge with BVDV-2. These results demonstrate the TDS-IM to be effective as a delivery system for a BVDV DNA vaccine in newborn calves in the presence of maternal antibodies, which supports the potential of electroporation as a delivery method for prophylactic DNA vaccines. Copyright © 2010. Published by Elsevier Ltd.
Source … |
|
|
Efficient delivery of DNA vaccines using human papillomavirus pseudovirions. |
|
We have examined non-replicative human papillomavirus (HPV) pseudovirions as an approach in the delivery of naked DNA vaccines without safety concerns associated with live viral vectors. In this study, we have generated HPV-16 pseudovirions encapsidating a DNA vaccine encoding the model antigen, ovalbumin (OVA) (HPV16-OVA pseudovirions). Vaccination with HPV16-OVA pseudovirions subcutaneously elicited significantly stronger OVA-specific CD8+ T-cell immune responses compared with OVA DNA vaccination via gene gun in a dose-dependent manner. We showed that a single amino acid mutation in the L2 minor capsid protein that eliminates the infectivity of HPV16-OVA pseudovirion significantly decreased the antigen-specific CD8+ T-cell responses in vaccinated mice. Furthermore, a subset of CD11c+ cells and B220+ cells in draining lymph nodes became labeled on vaccination with fluorescein isothiocyanate-labeled HPV16-OVA pseudovirions in injected mice. HPV pseudovirions were found to infect bone marrow-derived dendritic cells (BMDCs) in vitro. We also showed that pretreatment of HPV16-GFP pseudovirions with furin leads to enhanced HPV16-OVA pseudovirion infection of BMDCs and OVA antigen presentation. Our data suggest that DNA vaccines delivered using HPV pseudovirions represent an efficient delivery system that can potentially affect the field of DNA vaccine delivery.Gene Therapy advance online publication,
Source … |
|
|
DermaVir Presented at 7th Int Conf on Nanosciences/Nanotech |
|
 Immunacia’s Genetic Immunity Presents DermaVir at the 7th International Conference on Nanosciences & Nanotechnologies – A Unique DNA Nanomedicine for Therapeutic HIV Vaccine
Budapest, Hungary and McLean, VA – 12 July, 2010 – Julianna Lisziewicz, PhD, President of Genetic Immunity, a biopharmaceutical company developing nanomedicine-based immunotherapies, is an invited speaker at this week’s 7th International Conference on Nanosciences & Nanotechnologies in Ouranoupolis Halkidiki, Greece. The conference gathers front-line researchers, scientists and industry experts specialized in nanotechnology applications. Leading experts such as Dr. Lisziewicz are invited to present lectures covering the latest research in this rapidly progressing field. Dr. Lisziewicz has been invited to present the Company’s development of DermaVir, the first nanomedicine-based therapeutic vaccine for HIV/AIDS, on Tuesday, July 13th. |
|
|
|
